Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension

Oliver Chung, Wanpen Vongpatanasin, Klaus Bonaventura, Yair Lotan, Christian Sohns, Wilhelm Haverkamp, Marc Dorenkamp

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Nonadherence to drug therapy poses a significant problem in the treatment of patients with presumed resistant hypertension. It has been shown that therapeutic drug monitoring (TDM) is a useful tool for detecting nonadherence and identifying barriers to treatment adherence, leading to effective blood pressure (BP) control. However, the cost-effectiveness of TDM in the management of resistant hypertension has not been investigated. Method: A Markov model was used to evaluate life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in resistant hypertension patients receiving either TDM optimized therapy or standard best medical therapy. The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and mortality. Cost analyses were performed from a payer's perspective. Deterministic and probabilistic sensitivity analyses were conducted. Results: In the age group of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at additional costs of €3854 and €3922, respectively. Given a willingness-to-pay threshold of €35 000 per QALY gained, the probability of TDM being cost-effective was 95% or more in all age groups from 30 to 90 years. Results were influenced mostly by the frequency of TDM testing, the rate of nonresponders to TDM, and the magnitude of effect of TDM on BP. Conclusion: Therapeutic drug monitoring presents a potential cost-effective healthcare intervention in patients diagnosed with resistant hypertension. Importantly, this finding is valid for a wide range of patients, independent of sex and age.

Original languageEnglish (US)
Pages (from-to)2411-2421
Number of pages11
JournalJournal of Hypertension
Volume32
Issue number12
DOIs
StatePublished - 2014

Fingerprint

Drug Monitoring
Cost-Benefit Analysis
Hypertension
Quality-Adjusted Life Years
Costs and Cost Analysis
Age Groups
Blood Pressure
Therapeutics
Health Care Costs
Quality of Life
Morbidity
Drug Therapy
Mortality

Keywords

  • Cardiovascular diseases
  • Cost and cost analysis
  • Cost-benefit analysis
  • Drug monitoring
  • Hypertension
  • Medication adherence
  • Probability
  • Risk assessment

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. / Chung, Oliver; Vongpatanasin, Wanpen; Bonaventura, Klaus; Lotan, Yair; Sohns, Christian; Haverkamp, Wilhelm; Dorenkamp, Marc.

In: Journal of Hypertension, Vol. 32, No. 12, 2014, p. 2411-2421.

Research output: Contribution to journalArticle

Chung, Oliver ; Vongpatanasin, Wanpen ; Bonaventura, Klaus ; Lotan, Yair ; Sohns, Christian ; Haverkamp, Wilhelm ; Dorenkamp, Marc. / Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. In: Journal of Hypertension. 2014 ; Vol. 32, No. 12. pp. 2411-2421.
@article{d1c35153c6f14f3ca9a88085830ee2b0,
title = "Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension",
abstract = "Background: Nonadherence to drug therapy poses a significant problem in the treatment of patients with presumed resistant hypertension. It has been shown that therapeutic drug monitoring (TDM) is a useful tool for detecting nonadherence and identifying barriers to treatment adherence, leading to effective blood pressure (BP) control. However, the cost-effectiveness of TDM in the management of resistant hypertension has not been investigated. Method: A Markov model was used to evaluate life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in resistant hypertension patients receiving either TDM optimized therapy or standard best medical therapy. The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and mortality. Cost analyses were performed from a payer's perspective. Deterministic and probabilistic sensitivity analyses were conducted. Results: In the age group of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at additional costs of €3854 and €3922, respectively. Given a willingness-to-pay threshold of €35 000 per QALY gained, the probability of TDM being cost-effective was 95{\%} or more in all age groups from 30 to 90 years. Results were influenced mostly by the frequency of TDM testing, the rate of nonresponders to TDM, and the magnitude of effect of TDM on BP. Conclusion: Therapeutic drug monitoring presents a potential cost-effective healthcare intervention in patients diagnosed with resistant hypertension. Importantly, this finding is valid for a wide range of patients, independent of sex and age.",
keywords = "Cardiovascular diseases, Cost and cost analysis, Cost-benefit analysis, Drug monitoring, Hypertension, Medication adherence, Probability, Risk assessment",
author = "Oliver Chung and Wanpen Vongpatanasin and Klaus Bonaventura and Yair Lotan and Christian Sohns and Wilhelm Haverkamp and Marc Dorenkamp",
year = "2014",
doi = "10.1097/HJH.0000000000000346",
language = "English (US)",
volume = "32",
pages = "2411--2421",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension

AU - Chung, Oliver

AU - Vongpatanasin, Wanpen

AU - Bonaventura, Klaus

AU - Lotan, Yair

AU - Sohns, Christian

AU - Haverkamp, Wilhelm

AU - Dorenkamp, Marc

PY - 2014

Y1 - 2014

N2 - Background: Nonadherence to drug therapy poses a significant problem in the treatment of patients with presumed resistant hypertension. It has been shown that therapeutic drug monitoring (TDM) is a useful tool for detecting nonadherence and identifying barriers to treatment adherence, leading to effective blood pressure (BP) control. However, the cost-effectiveness of TDM in the management of resistant hypertension has not been investigated. Method: A Markov model was used to evaluate life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in resistant hypertension patients receiving either TDM optimized therapy or standard best medical therapy. The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and mortality. Cost analyses were performed from a payer's perspective. Deterministic and probabilistic sensitivity analyses were conducted. Results: In the age group of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at additional costs of €3854 and €3922, respectively. Given a willingness-to-pay threshold of €35 000 per QALY gained, the probability of TDM being cost-effective was 95% or more in all age groups from 30 to 90 years. Results were influenced mostly by the frequency of TDM testing, the rate of nonresponders to TDM, and the magnitude of effect of TDM on BP. Conclusion: Therapeutic drug monitoring presents a potential cost-effective healthcare intervention in patients diagnosed with resistant hypertension. Importantly, this finding is valid for a wide range of patients, independent of sex and age.

AB - Background: Nonadherence to drug therapy poses a significant problem in the treatment of patients with presumed resistant hypertension. It has been shown that therapeutic drug monitoring (TDM) is a useful tool for detecting nonadherence and identifying barriers to treatment adherence, leading to effective blood pressure (BP) control. However, the cost-effectiveness of TDM in the management of resistant hypertension has not been investigated. Method: A Markov model was used to evaluate life-years, quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios in resistant hypertension patients receiving either TDM optimized therapy or standard best medical therapy. The model ran from the age of 30 to 100 years or death, using a cycle length of 1 year. Efficacy of TDM was modeled by reducing risk of hypertension-related morbidity and mortality. Cost analyses were performed from a payer's perspective. Deterministic and probabilistic sensitivity analyses were conducted. Results: In the age group of 60-year olds, TDM gained 1.07 QALYs in men and 0.97 QALYs in women at additional costs of €3854 and €3922, respectively. Given a willingness-to-pay threshold of €35 000 per QALY gained, the probability of TDM being cost-effective was 95% or more in all age groups from 30 to 90 years. Results were influenced mostly by the frequency of TDM testing, the rate of nonresponders to TDM, and the magnitude of effect of TDM on BP. Conclusion: Therapeutic drug monitoring presents a potential cost-effective healthcare intervention in patients diagnosed with resistant hypertension. Importantly, this finding is valid for a wide range of patients, independent of sex and age.

KW - Cardiovascular diseases

KW - Cost and cost analysis

KW - Cost-benefit analysis

KW - Drug monitoring

KW - Hypertension

KW - Medication adherence

KW - Probability

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=84927786253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927786253&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000000346

DO - 10.1097/HJH.0000000000000346

M3 - Article

C2 - 25255395

AN - SCOPUS:84927786253

VL - 32

SP - 2411

EP - 2421

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 12

ER -